Skip to Content

Clinical Studies

Trial Evaluating an Investigational Agent for Management of Oral Melanoma in Dogs - Richmond Location

CURRENTLY ENROLLING

This trial is designed to evaluate the effectiveness of a novel therapy in dogs with oral melanoma.

STUDY DETAILS


Trial Evaluating an Investigational Agent for Management of Oral Melanoma in Dogs - Springfield Location

CURRENTLY ENROLLING

This trial is designed to evaluate the effectiveness of a novel therapy in dogs with oral melanoma.

STUDY DETAILS


Dysbiosis Enhancing Linkage Towards Association with Canine Osteosarcoma (DEL-TACO Lite) - Leesburg Location

CURRENTLY ENROLLING

Intestinal dysbiosis has been associated with tumor progression of colorectal, lung, and breast cancer in human patients. The objective of this study is to determine whether or not canine patients diagnosed with osteosarcoma have intestinal dysbiosis and if the presence of intestinal dysbiosis is associated with metastasis in these patients.

STUDY DETAILS


Dysbiosis Enhancing Linkage Towards Association with Canine Osteosarcoma (DEL-TACO Lite) - Springfield Location

CURRENTLY ENROLLING

Intestinal dysbiosis has been associated with tumor progression of colorectal, lung, and breast cancer in human patients. The objective of this study is to determine whether or not canine patients diagnosed with osteosarcoma have intestinal dysbiosis and if the presence of intestinal dysbiosis is associated with metastasis in these patients.

STUDY DETAILS


Dysbiosis Enhancing Linkage Towards Association with Canine Osteosarcoma (DEL-TACO Lite) - Richmond Location

CURRENTLY ENROLLING

Intestinal dysbiosis has been associated with tumor progression of colorectal, lung, and breast cancer in human patients. The objective of this study is to determine whether or not canine patients diagnosed with osteosarcoma have intestinal dysbiosis and if the presence of intestinal dysbiosis is associated with metastasis in these patients.

STUDY DETAILS


Evaluating the Tolerability of Combination of Verdinexor and Doxorubicin in Dogs with Cancer - Richmond Location

CLOSED

Verdinexor is a chemotherapy drug that has been conditionally approved by the FDA for the treatment of canine lymphoma. Verdinexor is a selective inhibitor of nuclear export (SINE) compound, and this family of drug has demonstrated encouraging results in preclinical studies when combined with other chemotherapeutic drugs.

STUDY DETAILS


Trial Evaluating an Investigational Agent for Management of Transitional Cell Carcinoma - Richmond Location

CLOSED

This trial is designed to evaluate the safety and preliminary pain management and anti-cancer effectiveness of a novel therapy in dogs with bladder transitional cell carcinoma (TCC).

STUDY DETAILS


Back to top